ClinicalTrials.gg
CompletedNCT05049447Updated Sep 20, 2021

Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety

A Phase 4 interventional study of Pascoflair and Placebo in Stress, Brain Activity and Passiflora Incarnata, sponsored by Pascoe Pharmazeutische Praeparate GmbH. Completed. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-09-20.

Sponsored by Pascoe Pharmazeutische Praeparate GmbH · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Proof of effectiveness of Pascoflair using qantitative measurement of electric brain activity during examination stress in 40 subjects suffering from test anxiety. A double-blind, randomized, placebo-controlled, 2-armed, Phase IV study in parallel design.

Read the detailed description

Anxiolytic effects of PASCOFLAIR® shall be tested in subjects suffering from test anxiety after single intake by aid of a newly developed, validated method consisting of a combination of eye tracking (following glances) with neurocode tracking (quantitative EEG with a time resolution of 364 ms).

02

Conditions studied

  • Stress
  • Brain Activity
  • Passiflora Incarnata
  • Test Anxiety
03

In context

Lead sponsor

Pascoe Pharmazeutische Praeparate GmbH is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects.
  • Age between 18 and 40 years (both included).
  • Anxiety questionnaire PAF (pre-selection of subjects) - values above T> 60 are regarded as conclusive.
  • Inconclusive case history and diagnosis.
  • Subject must be capable of giving .
  • Acceptance of written consent to participate in the study after education in written and oral form (informed consent).

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic disease with an impact on the study, which becomes obvious by case history or clinical examination.
  • pathological findings from clinical and laboratory findings.
  • Presence of clinically relevant pathological EEG features or artifact-free portion of the screening EEG \<30%.
  • Clinically relevant allergic symptoms.
  • Detection of alcohol at the time of initial examination (day SC) or on study day A (positive alcohol test) or by case history.
  • Detection of drugs (positive drug test) at the time of initial examination (day SC).
  • Consumption of clinically relevant medication during last fourteen days before and during the active study period based on the notification of the subject or his case history.
  • Consumption of medication with primarily central action (i.e. psychotropic drugs or centrally acting antihypertensives).
  • Known intolerance / (allergy) to plant derived extracts (Passion flower dry extract) or any of the ingredients of the product (anamnestic).
  • Presence of a rare, genetic disease such as fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase deficiency (anamnestic).
  • (Body Mass Index) \<18 or> 32.
  • Consumption of unusual quantities or misuse of coffee (more than 4 cups a day), tea (more than 4 cups a day) or tobacco (more than 20 cigarettes per day).
  • Smoking on day of A.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Verum arm

    Intervention: Drug: Verum (Pascoflair)

    Drug: Pascoflair

  • Placebo comparator
    Placebo arm

    Intervention: Drug: Placebo

    Other: Placebo

Interventions

  • DrugPascoflair

    1 x 2 tablets (single-dose)

  • OtherPlacebo

    1 x 2 tablets (single-dose)

06

What researchers measure

Primary outcomes

  1. Comparison of verum and placebo Beta 1 power

    Comparison of verum and placebo efficacy is performed on electric power in 17 different brain regions within six frequency ranges defined as target parameters in the presence of different stress inducing cognitive tests or exciting video scenes

    Time frame: day A (treatment day) - 1 day

Secondary outcomes

  1. Tolerability in a 4- Point scale

    Tolerability in a 4- Point scale (very good, good, moderately, poor)

    Time frame: Final examination (day AB) -1 day

  2. Correlation between questionnaire items and spectral EEG power with regard to different frequency ranges.

    Correlation between questionnaire items and spectral EEG power with regard to different frequency ranges.

    Time frame: Final examination - 1 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05049447
Lead sponsor
Pascoe Pharmazeutische Praeparate GmbH
Collaborators
NeuroCode AG
Responsible party
Sponsor
First posted
Sep 20, 2021
Start date
May 2015
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Sep 20, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion